








































































































RANK	 DRUG:	CONCENTRATION	 	 	 	 								SCORE					NATURE	/	FUNCTION	 	
1______PIROMIDIC	ACID:100	 11.40							Quinolone	antibiotic	
2______CEFAMANDOLE	NAFATE:100	 13.71							Cephalosporin	antibiotic	3______CEFUROXIME	SODIUM:100	 15.52							Cephalosporin	antibiotic	4______CARPROFEN:10	 16.15							COX	inhibitor	/	NSAID	5______PRALIDOXIME	MESYLATE:100	 17.40							Antidote	for	organophosphate	poisoning	6______ESTRIOL	BENZYL	ETHER:10000	 18.21							Oestrogen	steroid	hormone	
7______ESTRADIOL-3-SULFATE:100	 18.79							Oestrogen	steroid	hormone	
8______LOMEFLOXACIN	HYDROCHLORIDE:100	 19.10							Fluoroquinolone	antibiotic		9______METAMPICILLIN	SODIUM:100	 19.65							b-lactam	antibiotic		10_____ESTRIOL	BENZYL	ETHER:100	 20.52							Oestrogen	steroid	hormone	11_____5-FLUORO-5'-DEOXYURIDINE:100	 20.62							Inhibitor	of	thymidine	synthesis	
12_____FOSFOMYCIN:100	 21.85							Phosphonic	acid	antibiotic	13_____CEFAMANDOLE	NAFATE:10000	 22.10							Cephalosporin	antibiotic	
14_____KETOPROFEN:100	 22.29							COX	inhibitor	/	NSAID	15_____ESTRADIOL	ACETATE:100	 22.30							Oestrogen	steroid	hormone	16_____METHYLERGONOVINE	MALEATE:10000	 23.22							Inducer	of	smooth	muscle	contraction	17_____RETINOL:100	 24.47							Vitamin	A	18_____PINDOLOL:100	 24.59								b-Adrenoceptor	antagonist	19_____OFLOXACIN:100	 24.92							Fluoroquinolone	antibiotic	20_____TOLFENAMIC	ACID:100	 26.31							COX	inhibitor	/	NSAID	21_____IODIPAMIDE:10000	 26.40							Radiopaque	contrast	medium	22_____PIROMIDIC	ACID:10	 26.71							Quinolone	antibiotic	23_____MEFENAMIC	ACID:100	 27.18							COX	inhibitor	/	NSAID	24_____BUTAMBEN:10000	 27.92							Anaesthetic	25_____FENSPIRIDE	HYDROCHLORIDE:100	 28.76							Antitussive	/	anti-inflammatory	26_____EPHEDRINE	(1R,2S)	HYDROCHLORIDE:100	 28.89							b-Adrenoceptor	agonist	/	bronchodilator	27_____DIETHYLTOLUAMIDE:1000	 29.13							Insect	repellant	28_____CARPROFEN:100	 29.70							COX	inhibitor	/	NSAID	29_____HECOGENIN:10000	 29.71							Steroid	saponin	30_____AMLEXANOX:100	 30.05							Anti-inflammatory/anti-allergic	agent	31_____GALANTHAMINE	HYDROBROMIDE:10000	 30.35							Alkaloid	used	in	dementia	treatment	
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Let	!"#$% 	correspond	to	molecule	n’s	signal	for	sample	' ∈ {0,1},	drug	. ∈ ℤ01234	and	concentration	5 ∈ ℤ06.		Where	'	=0	when	the	sample	is	a	C33Y	mutation	and	'	=1	when	the	sample	is	a	WT,	.	Î	[1361,1376]	for	the	DMSO	1-16	samples	and	1	to	1360	for	the	other	drug	samples	and	5	is	the	log	to	the	base	10	of	the	samples	drug	concentration.	Then	<% = {!"#$% }	is	the	set	of	all	the	signals	returned	by	the	micro-array	for	molecule	>,	where		> ∈ ℤ06?.		We	calculate	the	distance	between	the	signal	intensities	for	samples	corresponding	to	C33Y	given	drug	'	and	the	samples	corresponding	to	WT	with	no	drug	(.	Î	[1361, 1376])	at	concentration	k	as,	
A"$ = (	!?"$% 	− 	DEA'F> {!1241"$% , !124G"$% , … , !1234"$% } )IJK {!1241"$% , !124G"$% , … , !1234"$% }% 	Where,	for	each	antibody,	this	calculates	the	difference	between	the	signal	for	the	C33Y	given	drug	'	at	concentration	5	minus	the	median	signal	for	the	WT	given	DMSO	at	concentration	5	divided	by	the	inter	quartile	range	(IQR)	of	the	signal	for	the	WT	given	DMSO	at	concentration	5.	This	is	effectively	a	weighted	sum,	where	more	emphasis	is	added	to	the	drug	and	concentration	pairs	that	appear	to	have	less	signal	variance	in	the	wild	type	patients.	The	sum	over	all	the	molecules	gives	the	overall	measure	of	difference	between	the	C33Y	TRAPs	patient	given	drug	'	at	concentration	5	and	the	WT	patient	given	no	drug.		Finally,	we	find	the	best	concentration	for	drug	'	by	finding,	argmin$ {A"$}.	We	then	return	the	rank	of	drug	'	and	concentration	5	in	ascending	order	of	the	measure	A"$ .	Clinical	experts	reviewed	the	ranked	list	and	chose	7	drugs	to	be	investigated	in	more	detail	based	on	the	rank.	How	were	step	1	results	used	to	identify	the	drugs?	
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Step	2	2a)	Data	creation	For	step	2,	as	in	step	1,	we	had	the	40	molecule	signals	at	four	concentrations	of	the	drugs	of	interest.		The	calculations	are	exemplified	here	for	5	C33Y	TRAPs	patients	and	4	WT	healthy	control	subjects	without	the	mutation	for	each	molecule	and	concentration.	2b)	Preprocessing	After	normalizing	the	micro	array	data	we	removed	any	potential	signal	outliers.	For	each	set	of	C33Y	patients	or	each	set	of	WT	patients	we	calculated	the	median	absolute	deviation	(MAD)	for	each	drug	and	concentration	combination.		Any	signal	that	was	three	times	the	MAD	away	from	the	median	signal	of	the	group	was	removed.	2c)	Investigating	interaction	importance	To	model	the	data	(with	outliers	removed),	we	applied	mixed-effect	models	of	the	form:	RST = 	UVW +	YTZT +	[S	ZT	~	] ^,_ 																	[S	~	] ^, `abS 									Where	RST ∈ ℝad	e	f	is	the	signals	observed	for	the	9	patients,	taking	7	different	drugs	at	4	different	concentrations,	UV 	∈ ℝad	e	g	is	the	matrix	of	fixed	effects,	W ∈ℝf	e	g	is	the	vector	of	fixed	effect	coefficients,	h# ∈ ℝi	j	1	is	the	random	effects,	k#	 ∈ℝ 	is	the	random	effects	coefficient	(per	patient	random	effect),		l" 	is	the	252	x	1	vector	of	errors	for	observations,	m	is	the	q	x	q	covariance	matrix	for	the	random	effects	and	nGΛ"is	the	4	x	4	covariance	matrix	for	the	errors.			For	each	drug	and	molecule,	the	two	mixed-effect	models	applied	were,	
• Model	1:		
	 4	
RST = Wp +	WaqrstS + WuvswS + Wxyz{yS + W|qrstSvswS +																						W}qrstSyz{yS + W~vswSyz{yS + WdqrstSvswSyz{yS +																					ZT + [S		
• Model	2:		RST = 	Wp +	WaqrstS + WuvswS + Wxyz{yS + W|qrstSyz{yS																								+W}vswSyz{yS + ZT + [S			where	RST	is	the	ith	signal	reading	of	the	molecule	for	patient	j,		qrstS	is	an	indicator	of	whether	the	drug	of	interest	was	given	to	the	patient	j	for	the	ith	signal	reading,	vswS	is	an	indicator	of	whether	the	patient	j	had	the	TRAPs	mutation	and	yz{yS	is	the	log10	of	the	concentration	of	the	drug	given	for	the	ith	signal	reading	of	patient	j.		The	random	effects	term	ZT	means	than	patient	variation	is	included	into	the	models,	with	the	random	effect	coming	from	a	Normal	distribution	with	0	mean.	The	second	equation	excludes	both	the	interaction	between	the	drug	and	mutation	and	the	interaction	between	concentration,	mutation	and	drug.		We	then	applied	a	log	likelihood-ratio	test	to	determine	whether	the	first	model	(including	the	additional	interactions)	significantly	improved	the	model	compared	to	the	second	model	fit	while	accounting	for	the	additional	complexity	of	the	model	with	the	interaction	terms.		We	used	a	significant	level	of	10%	due	to	the	small	number	of	samples	limiting	the	power	of	the	analysis.				2d)	Alleviating	vs	exacerbating	the	difference	In	the	previous	step	we	have	identified	the	drugs	that	potentially	cause	patients	with	the	TRAPs	mutation	to	have	a	different	molecule	signal	dynamic	compared	to	patients	without	the	mutation	and	drug.		However,	this	does	not	tell	us	whether	the	drug	exacerbates	or	alleviates	the	different	in	the	antibody	signal	between	the	patients	with	TRAPs	and	those	without.	We	want	to	find	drugs	that	normalise	the	TRAP’s	mutation	molecule	signals	(e.g.	make	them	representative	of	the	signal	for	wild	type	patients	taking	no	drug).	To	investigate	this,	we	also	calculated	the	fixed	effect	coefficients	for	model	3,	
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RS = 	W^ + Wpqrst: ÄSvsw: ÄSyz{yS + Waqrst: ÅSvsw: ÄSyz{yS +Wuqrst: ÄSvsw: ÅSyz{yS +	Wxqrst: ÅSvsw: ÅSyz{yS + ZS + [S		
	We	use	model	3	to	determine	whether	the	coefficient	of	the	fixed	effect	corresponding	to	taking	the	drug	when	the	patient	had	the	mutation	(Wp)	was	less	than	the	coefficient	of	the	fixed	effect	corresponding	to	not	taking	the	drug	when	the	patient	did	not	have	the	mutation	(Wx).		Justification	of	this	is	that	the	patients	with	the	mutation	have	an	elevated	signal	for	the	molecules	investigated,	so	if	the	presence	of	the	drug	and	mutation	interaction	is	causing	the	signal	to	decrease	at	a	greater	rate	(or	increase	at	a	slower	rate)	than	the	absence	of	the	drug	and	mutation	interaction	over	concentration,	then	this	suggests	the	TRAPs	patients’	signals	are	normalizing	as	the	drugs	concentration	increases.		2e)	Combining	results	Finally,	we	calculate	the	number	of	molecule	for	each	drug	where	the	likelihood	test	showed	a	significant	interaction	between	the	drug,	concentration	and	mutation	(model	1	fit	the	data	better	than	model	2)	and	the	drug	showed	signs	of	normalizing	the	molecule’s	signal	(coefficient	Wpwas	less	than	Wx	in	model	3).		
